# SCORE Search Results Details for Application 10520296 and Search Result 20080731_165444_us-10-520-296-4.oligo.rag.

Score Home Page | Retrieve Application List | SCORE System Overview | SCORE FAQ | Comments / Suggestions

This page gives you Search Results detail for the Application 10520296 and Search Result 20080731_165444_us-10-520-296-4.oligo.rag.

Go Back to previous page

```
                          GenCore version 6.2.1
                    Copyright (c) 1993 - 2008  Biocceleration Ltd.


OM protein - protein search, using sw model

Run on:         July 31, 2008, 17:13:00 ; Search time 66 Seconds
                                          (without alignments)
                                          63.680 Million cell updates/sec

Title:          US-10-520-296-4
Perfect score:  7
Sequence:       1 ASSTDWS 7

Scoring table:  OLIGO
                Gapop 60.0 , Gapext 60.0

Searched:       3405708 seqs, 601879884 residues

Word size :     1

Total number of hits satisfying chosen parameters:      3299416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database :       A_Geneseq_200711:*
                1:  geneseqp1980s:*
                2:  geneseqp1990s:*
                3:  geneseqp2000:*
                4:  geneseqp2001:*
                5:  geneseqp2002:*
                6:  geneseqp2003a:*
                7:  geneseqp2003b:*
                8:  geneseqp2004a:*
                9:  geneseqp2004b:*
                10:  geneseqp2005:*
                11:  geneseqp2006:*
                12:  geneseqp2007:*

      Pred. No. is the number of results predicted by chance to have a
      score greater than or equal to the score of the result being printed,
      and is derived by analysis of the total score distribution.

                                    SUMMARIES
                 %
Result           Query
   No.    Score  Match Length DB  ID                      Description
 ---------------------------------------------------------------------------
     1        7  100.0       7  8  ADG14605                Adg14605 MBP83-89-
     2        6   85.7     115  5  ADK35926                Adk35926 Novel hum
     3        6   85.7     480  7  ADE81195                Ade81195 Orf11, SE
     4        6   85.7     547  4  AAE07054                Aae07054 Human gen
```

| | | | | | | |
|---|---|---|---|---|---|---|
| 5 | 6 | 85.7 | 547 | 5 | ABG65102 | Abg65102 Human alb |
| 6 | 6 | 85.7 | 547 | 6 | ADA55049 | Ada55049 Human pro |
| 7 | 6 | 85.7 | 547 | 8 | ADL78369 | Adl78369 Albumin f |
| 8 | 6 | 85.7 | 547 | 10 | AEE04690 | Aee04690 Cancer-as |
| 9 | 6 | 85.7 | 547 | 10 | AEE04692 | Aee04692 Cancer-as |
| 10 | 6 | 85.7 | 547 | 11 | AEH08642 | Aeh08642 Therapeut |
| 11 | 6 | 85.7 | 547 | 12 | AGI51470 | Agi51470 Human The |
| 12 | 6 | 85.7 | 594 | 5 | ABU60933 | Abu60933 Lung spec |
| 13 | 6 | 85.7 | 594 | 5 | ABU60982 | Abu60982 Lung spec |
| 14 | 5 | 71.4 | 10 | 4 | AAG94691 | Aag94691 Human com |
| 15 | 5 | 71.4 | 11 | 10 | AEC09392 | Aec09392 DNA helic |
| 16 | 5 | 71.4 | 12 | 11 | AEI90313 | Aei90313 SARS coro |
| 17 | 5 | 71.4 | 15 | 2 | AAW62155 | Aaw62155 Agrobacte |
| 18 | 5 | 71.4 | 15 | 8 | ADJ25836 | Adj25836 Beta-gluc |
| 19 | 5 | 71.4 | 15 | 10 | ADZ48583 | Adz48583 A. faecae |
| 20 | 5 | 71.4 | 20 | 10 | ADZ98110 | Adz98110 Human ami |
| 21 | 5 | 71.4 | 34 | 10 | AEA28141 | Aea28141 Sericin p |
| 22 | 5 | 71.4 | 35 | 11 | AEE36720 | Aee36720 Human ser |
| 23 | 5 | 71.4 | 39 | 10 | AED81597 | Aed81597 Neurofila |
| 24 | 5 | 71.4 | 44 | 11 | AES91312 | Aes91312 S. agalac |
| 25 | 5 | 71.4 | 49 | 4 | ABG13455 | Abg13455 Novel hum |
| 26 | 5 | 71.4 | 53 | 8 | AFP91643 | Afp91643 Glycine m |
| 27 | 5 | 71.4 | 53 | 9 | AFQ73379 | Afq73379 Glycine m |
| 28 | 5 | 71.4 | 55 | 6 | ABU36051 | Abu36051 Protein e |
| 29 | 5 | 71.4 | 55 | 7 | ADC88674 | Adc88674 Ribosomal |
| 30 | 5 | 71.4 | 55 | 10 | AEA79379 | Aea79379 Novel M. |
| 31 | 5 | 71.4 | 55 | 10 | AEB03476 | Aeb03476 Mycobacte |
| 32 | 5 | 71.4 | 56 | 4 | AAU67046 | Aau67046 Propionib |
| 33 | 5 | 71.4 | 56 | 4 | AAU56963 | Aau56963 Propionib |
| 34 | 5 | 71.4 | 56 | 6 | ABM53482 | Abm53482 Propionib |
| 35 | 5 | 71.4 | 56 | 6 | ABM63565 | Abm63565 Propionib |
| 36 | 5 | 71.4 | 59 | 12 | AFK94093 | Afk94093 SH3 domai |
| 37 | 5 | 71.4 | 59 | 12 | AFK96536 | Afk96536 Natural S |
| 38 | 5 | 71.4 | 61 | 4 | AAU58790 | Aau58790 Propionib |
| 39 | 5 | 71.4 | 61 | 6 | ABM55309 | Abm55309 Propionib |
| 40 | 5 | 71.4 | 62 | 4 | AAU43260 | Aau43260 Propionib |
| 41 | 5 | 71.4 | 62 | 6 | ABM39779 | Abm39779 Propionib |
| 42 | 5 | 71.4 | 64 | 5 | ADK35271 | Adk35271 Novel hum |
| 43 | 5 | 71.4 | 65 | 9 | AFQ72038 | Afq72038 Glycine m |
| 44 | 5 | 71.4 | 67 | 4 | AAU14969 | Aau14969 Novel bon |
| 45 | 5 | 71.4 | 67 | 4 | AAU14929 | Aau14929 Novel bon |

ALIGNMENTS

RESULT 1
ADG14605
ID  ADG14605 standard; peptide; 7 AA.
XX
AC  ADG14605;
XX
DT  11-MAR-2004  (first entry)
XX
DE  MBP83-89-reactive TCR CDR3 sequence, SEQ ID NO:4.
XX
KW  T cell receptor; TCR; MBP; myelin basic protein; MBP83-89 epitope;
KW  complementarity determining region; CDR3; MBP83-89-reactive TCR CDR3;
KW  autoimmune disease; vaccine; rheumatoid arthritis; myasthenia gravis;
KW  systemic lupus erythematosus; autoimmune thyroiditis; Graves' disease;
KW  inflammatory bowel disease; autoimmune uveoretinitis; polymyositis;
KW  diabetes; multiple sclerosis; MS; antiarthritic; antirheumatic; muscular;
KW  neuroprotective; antiinflammatory; dermatological; immunosuppressive;
KW  antithyroid; gastrointestinal; antidiabetic; human.
XX
OS  Homo sapiens.
XX
PN  WO2003104407-A2.
XX
PD  18-DEC-2003.
XX
PF  05-JUN-2003; 2003WO-US017873.
XX
PR  05-JUN-2002; 2002US-0386287P.
XX
PA  (BAYU ) BAYLOR COLLEGE MEDICINE.

```
PA   (OPEX-) OPEXA PHARM INC.
XX
PI   Zhang JZ;
XX
DR   WPI; 2004-062334/06.
DR   N-PSDB; ADG14602.
XX
PT   New oligonucleotide encoding a peptide, useful for diagnosing, monitoring
PT   or treating autoimmune diseases e.g. rheumatoid arthritis, myasthenia
PT   gravis, multiple sclerosis, systemic lupus erythematosus, autoimmune
PT   thyroiditis.
XX
PS   Claim 1; SEQ ID NO 4; 33pp; English.
XX
CC   The invention relates to oligonucleotides of 15-30 nucleotides in length
CC   encoding a CDR3 (complementarity determining region) sequence from a T
CC   cell receptor (TCR) reactive against the 83-99 immunodominant epitope of
CC   MBP (myelin basic protein). The invention also relates to a primer pair
CC   comprising an MBP83-89-reactive TCR CDR3 oligonucleotide and a TCR V-beta
CC   to C-beta region oligonucleotide; a labelled MBP83-89-reactive TCR CDR3
CC   oligonucleotide probe; a method of detecting MBP83-99 T cells expressing
CC   an MBP83-89-reactive TCR CDR3 motif; a vaccine comprising an MBP83-89-
CC   reactive TCR CDR3 peptide; and methods of monitoring and treating an
CC   autoimmune disease. The invention further discloses an antibody against
CC   an MBP83-89-reactive TCR CDR3 peptide. The vaccine of the invention may
CC   be used to treat autoimmune diseases including rheumatoid arthritis,
CC   myasthenia gravis, systemic lupus erythematosus, autoimmune thyroiditis,
CC   Graves' disease, inflammatory bowel disease, autoimmune uveoretinitis,
CC   polymyositis, certain types of diabetes, and especially multiple
CC   sclerosis (MS). The present sequence is related to the invention.
XX
SQ   Sequence 7 AA;

  Query Match             100.0%;  Score 7;  DB 8;  Length 7;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+06;
  Matches    7;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ASSTDWS 7
              |||||||
Db          1 ASSTDWS 7


RESULT 2
ADK35926
ID   ADK35926 standard; protein; 115 AA.
XX
AC   ADK35926;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Novel human polypeptide SeqID8008.
XX
KW   antiarthritic; antiparkinsonian; neuroprotective; nootropic;
KW   immunosuppressive; cytostatic; antipsoriatic; antiinflammatory;
KW   antibacterial; antiviral; antifungal; antiparasitic; gene therapy;
KW   arthritis; Parkinson's; Alzheimer's; autoimmune disease; cancer;
KW   psoriasis; inflammatory bowel disease; infection; bacteria; virus;
KW   fungus; parasite; human.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 1. .115
FT                   /label= OTHER
FT                   /note= "OTHER= All Xaa's in this sequence are unknown
FT                   amino acids or the site of a stop codon within the DNA
FT                   sequence"
XX
PN   WO200216439-A2.
XX
PD   28-FEB-2002.
XX
PF   05-MAR-2001; 2001WO-US004941.
XX
PR   07-MAR-2000; 2000US-00519705.
PR   19-MAY-2000; 2000US-00574454.
```

```
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Drmanac RT;
XX
DR   WPI; 2002-280918/32.
XX
PT   Isolated polynucleotide encoding bone marrow derived polypeptides useful
PT   for treating, e.g., Parkinson's, Alzheimer's, cancer, arthritis, Crohn's
PT   disease, and inflammatory bowel disease.
XX
PS   Claim 20; SEQ ID NO 8008; 504pp; English.
XX
CC   This invention relates to a novel isolated polynucleotide comprising a
CC   nucleotide sequence selected from one of 1680 sequences, a mature protein
CC   coding portion of them, an active domain of them and their complementary
CC   sequences. The invention may be useful for the production of compounds
CC   with an antiarthritic, antiparkinsonian, neuroprotective, nootropic,
CC   immunosuppressive, cytostatic, antipsoriatic, antiinflammatory,
CC   antibacterial, antiviral, antifungal or antiparasitic activity. In
CC   addition, the disclosed sequences may be useful for gene therapy. The
CC   polypeptides or their antibodies are useful for treating many diseases
CC   such as arthritis, Parkinson's, Alzheimer's, autoimmune diseases, cancer,
CC   psoriasis, inflammatory bowel disease and infections caused by bacteria,
CC   viruses, fungi or parasites. The present sequence is that of a human
CC   polypeptide of the invention.
XX
SQ   Sequence 115 AA;

  Query Match             85.7%;  Score 6;  DB 5;  Length 115;
  Best Local Similarity   100.0%;  Pred. No. 62;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ASSTDW 6
              ||||||
Db          2 ASSTDW 7


RESULT 3
ADE81195
ID   ADE81195 standard; protein; 480 AA.
XX
AC   ADE81195;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Orf11, SEQ ID 23.
XX
KW   ML-236B; HMG-CoA reducing enzyme; Orf11.
XX
OS   Penicillium citrinum.
XX
PN   JP2003116567-A.
XX
PD   22-APR-2003.
XX
PF   15-OCT-2001; 2001JP-00316578.
XX
PR   15-OCT-2001; 2001JP-00316578.
XX
PA   (SANY ) SANKYO CO LTD.
XX
DR   WPI; 2003-817677/77.
DR   N-PSDB; ADE81194.
XX
PT   Novel DNA associated with synthesis of ML-236B, useful for improving ML-
PT   236B production in ML-236B producing microbe.
XX
PS   Example 8; SEQ ID NO 23; 142pp; Japanese.
XX
CC   The present invention relates to a DNA sequence (I, ADE81173), which is
CC   associated with ML-236B synthesis. (I) is useful for improving ML-236B
CC   production in a HMG-CoA reducing-enzyme-inhibitor ML-236B producing
CC   microbe. The present sequence was used to illustrate the invention.
XX
SQ   Sequence 480 AA;
```

```
  Query Match             85.7%;  Score 6;  DB 7;  Length 480;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 SSTDWS 7
              ||||||
Db         88 SSTDWS 93


RESULT 4
AAE07054
ID   AAE07054 standard; protein; 547 AA.
XX
AC   AAE07054;
XX
DT   15-JUN-2007  (revised)
DT   16-OCT-2001  (first entry)
XX
DE   Human gene 4 encoded secreted protein HSYAB05, SEQ ID NO:71.
XX
KW   Human secreted protein; proliferative disorder; cancer; tumour;
KW   foetal abnormality; developmental abnormality; haematopoietic disorder;
KW   immune system disorder; AIDS; autoimmune disease; rheumatoid arthritis;
KW   inflammation; allergy; neurological disorder; Alzheimer's disease;
KW   Parkinson's disease; cognitive disorder; schizophrenia; asthma;
KW   skin disorder; psoriasis; sepsis; diabetes; atherosclerosis;
KW   cardiovascular disorder; angiogenic disorder; kidney disorder;
KW   gastrointestinal disorder; pregnancy-related disorder;
KW   endocrine disorder; infection; wound healing; vulnerary; cell culture;
KW   chemotaxis; food additive; gene therapy; binding partner identification;
KW   BOND_PC; KIAA1754; KIAA1754 [Homo sapiens]; bA127L20.2; RP11-127L20.4;
KW   hypothetical protein LOC85450;
KW   hypothetical protein LOC85450 [Homo sapiens]; 2; DANGER; bA127L20;
KW   KIAA1754, isoform CRA_a; KIAA1754, isoform CRA_a [Homo sapiens];
KW   novel protein; novel protein [Homo sapiens]; unnamed protein product;
KW   unnamed protein product [Homo sapiens].
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1. .15
FT                   /label= Signal_peptide
FT   Protein         16. .547
FT                   /label= Mature_human_secreted_protein
XX
PN   WO200154708-A1.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US001434.
XX
PR   31-JAN-2000; 2000US-0179065P.
PR   04-FEB-2000; 2000US-0180628P.
PR   18-AUG-2000; 2000US-0226279P.
PR   05-DEC-2000; 2000US-0251988P.
PR   05-JAN-2001; 2001US-0259678P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Komatsoulis GA,  Baker KP,  Birse CE,  Soppet DR;
PI   Olsen HS,  Moore PA,  Wei P,  Ebner R,  Duan DR,  Shi Y,  Choi GH;
PI   Fiscella M,  Ni J,  Ruben SM,  Barash SC;
XX
DR   WPI; 2001-488743/53.
DR   N-PSDB; AAD13348.
DR   PC:NCBI; gi29789287.
XX
PT   New isolated nucleic acids and polypeptides, useful for diagnosing,
PT   treating and/or preventing human diseases and disorders.
XX
PS   Claim 11; Page 489-491; 558pp; English.
XX
CC   AAD13345-AAD13401 represent cDNAs corresponding to 22 human secreted
CC   protein genes, and AAE07051-AAE07105 represent the proteins they encode.
CC   AAE07106-AAE07129 represent human secreted protein fragments or variants.
```

```
CC   The genes and their secreted proteins are useful for preventing, treating
CC   or ameliorating medical conditions, e.g., by protein or gene therapy.
CC   Pathological conditions can be diagnosed by determining the amount of the
CC   new protein in a sample or by determining the presence of mutations in
CC   the new genes. Specific uses are described for each of the 22 genes,
CC   based on the tissues in which they are most highly expressed, and include
CC   developing products for the diagnosis or treatment of proliferative
CC   disorders, cancer, tumours, foetal and developmental abnormalities,
CC   haematopoietic disorders, diseases of the immune system, AIDS, autoimmune
CC   diseases (e.g., rheumatoid arthritis), inflammation, allergies,
CC   neurological disorders (e.g., Alzheimer's disease, Parkinson's disease),
CC   cognitive disorders, schizophrenia, asthma, skin disorders (e.g.,
CC   psoriasis), sepsis, diabetes, atherosclerosis, cardiovascular disorders,
CC   angiogenic disorders, kidney disorders, gastrointestinal disorders,
CC   pregnancy-related disorders, endocrine disorders, and infections. The
CC   proteins can also be used to aid wound healing and epithelial cell
CC   proliferation, to prevent skin aging due to sunburn, to maintain organs
CC   before transplantation, for supporting cell culture of primary tissues,
CC   to regenerate tissues, to identify their cognate ligands or binding
CC   partners, and in chemotaxis, and can be used as a food additive or
CC   preservative to modify storage properties. Antibodies specific for a
CC   protein of the invention can be used in alleviating symptoms associated
CC   with the disorders mentioned above, and in diagnostic immunoassays e.g.,
CC   radioimmunoassay or enzyme linked immunosorbent assay (ELISA). The
CC   present sequence represents a human secreted protein of the invention
CC
CC   Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC   information from BOND.
XX
SQ   Sequence 547 AA;

  Query Match             85.7%;  Score 6;  DB 4;  Length 547;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ASSTDW 6
              ||||||
Db        375 ASSTDW 380


RESULT 5
ABG65102
ID   ABG65102 standard; protein; 547 AA.
XX
AC   ABG65102;
XX
DT   15-JUN-2007  (revised)
DT   27-AUG-2002  (first entry)
XX
DE   Human albumin fusion protein #1777.
XX
KW   Albumin fusion protein; therapeutic protein X; human albumin; HA;
KW   human serum albumin; HSA; cancer; reproductive disorder;
KW   digestive disorder; immune disorder; endocrine disorder;
KW   haematopoietic disorder; neural disorder; connective disorder;
KW   cytostatic; antiinfertility; antiinflammatory; antiulcer;
KW   immunomodulator; anti-HIV; antidiabetic; haemostatic; nootropic;
KW   neuroprotective; antiparkinsonian; antimicrobial; neuroleptic;
KW   osteopathic; antiarthritic; BOND_PC; KIAA1754; KIAA1754 [Homo sapiens];
KW   bA127L20.2; RP11-127L20.4; hypothetical protein LOC85450;
KW   hypothetical protein LOC85450 [Homo sapiens]; 2; DANGER; bA127L20;
KW   KIAA1754, isoform CRA_a; KIAA1754, isoform CRA_a [Homo sapiens];
KW   novel protein; novel protein [Homo sapiens]; unnamed protein product;
KW   unnamed protein product [Homo sapiens].
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200177137-A1.
XX
PD   18-OCT-2001.
XX
PF   12-APR-2001; 2001WO-US011988.
XX
PR   12-APR-2000; 2000US-0229358P.
PR   25-APR-2000; 2000US-0199384P.
```

```
PR   21-DEC-2000; 2000US-0256931P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Haseltine WA;
XX
DR   WPI; 2002-010886/01.
DR   PC:NCBI; gi29789287.
XX
PT   New fusion protein for treating disease e.g. diabetes comprises an
PT   albumin fused to a therapeutic protein.
XX
PS   Claim 1; Page 1750-1752; 2102pp; English.
XX
CC   The present invention relates to albumin fusion proteins comprising a
CC   therapeutic protein X and human albumin (HA, also known as human serum
CC   albumin, HSA). The proteins are useful for treating a disease or disorder
CC   that may be modulated by therapeutic protein X. The albumin extends the
CC   shelf-life of protein X, and may increase its biological in vitro/in vivo
CC   activity. The protein is useful for treating and diagnosing disorders
CC   such as cancer, reproductive disorders, digestive disorders (e.g. Crohn's
CC   disease, ulcerative colitis), immune disorders (e.g. acquired
CC   immunodeficiency syndrome, AIDS), endocrine disorders (e.g. diabetes),
CC   haematopoietic disorders, neural disorders (e.g. Alzheimer's,
CC   Parkinson's, Creutzfeldt-Jacob disease, encephalomyelitis, meningitis,
CC   schizophrenia), and connective disorders (e.g. osteoporosis, arthritis).
CC   ABG63326-ABG65518 represent albumin fusion proteins of the invention
CC
CC   Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC   information from BOND.
XX
SQ   Sequence 547 AA;

  Query Match             85.7%;  Score 6;  DB 5;  Length 547;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ASSTDW 6
              ||||||
Db        375 ASSTDW 380


RESULT 6
ADA55049
ID   ADA55049 standard; protein; 547 AA.
XX
AC   ADA55049;
XX
DT   15-JUN-2007  (revised)
DT   20-NOV-2003  (first entry)
XX
DE   Human protein, SEQ ID 2617.
XX
KW   Cytostatic; Anti-inflammatory; Osteopathic; Neuroprotective; Nootropic;
KW   Gene Therapy; human; secretory protein; membrane proteins; cancer;
KW   inflammatory disease; osteoporosis; neurological disease; BOND_PC;
KW   KIAA1754; KIAA1754 [Homo sapiens]; bA127L20.2; RP11-127L20.4;
KW   hypothetical protein LOC85450;
KW   hypothetical protein LOC85450 [Homo sapiens]; 2; DANGER; bA127L20;
KW   KIAA1754, isoform CRA_a; KIAA1754, isoform CRA_a [Homo sapiens];
KW   novel protein; novel protein [Homo sapiens]; unnamed protein product;
KW   unnamed protein product [Homo sapiens].
XX
OS   Homo sapiens.
XX
PN   EP1293569-A2.
XX
PD   19-MAR-2003.
XX
PF   21-MAR-2002; 2002EP-00006586.
XX
PR   14-SEP-2001; 2001JP-00328381.
PR   24-JAN-2002; 2002US-0350435P.
XX
PA   (HELI-) HELIX RES INST.
PA   (REAS-) RES ASSOC BIOTECHNOLOGY.
```

```
XX
PI   Isogai T,  Sugiyama T,  Otsuki T,  Wakamatsu A,  Sato H,  Ishii S;
PI   Yamamoto J,  Isono Y,  Hio Y,  Otsuka K,  Nagai K,  Irie R,  Tamechika I;
PI   Seki N,  Yoshikawa T,  Otsuka M,  Nagahari K,  Masuho Y;
XX
DR   WPI; 2003-395539/38.
DR   N-PSDB; ADA53410.
DR   PC:NCBI; gi29789287.
XX
PT   New polynucleotides encoding full-length polypeptides, e.g. secretory
PT   and/or membrane proteins, useful for developing medicines for diseases in
PT   which the gene is involved, or as target molecules for gene therapy.
XX
PS   Claim 14; SEQ ID NO 2617; 205pp; English.
XX
CC   The present invention relates to novel human secretory or membrane
CC   proteins (ADA54072-ADA55710) and their coding sequences (ADA52433-
CC   ADA54071). The coding sequences are useful in the gene therapy of
CC   diseases caused by abnormalities of the proteins, e.g. cancer,
CC   inflammatory diseases, osteoporosis or neurological disease.
CC
CC   Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC   information from BOND.
XX
SQ   Sequence 547 AA;

  Query Match             85.7%;  Score 6;  DB 6;  Length 547;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ASSTDW 6
              ||||||
Db        375 ASSTDW 380


RESULT 7
ADL78369
ID   ADL78369 standard; protein; 547 AA.
XX
AC   ADL78369;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Albumin fusion protein related therapeutic protein X, SEQ ID No 1851.
XX
KW   albumin fusion protein; cytostatic; antianaemic; antiarthritic;
KW   antiasthmatic; anti-HIV; immunosuppressive; antiinflammatory;
KW   antipsoriatic; antibacterial; osteopathic; dermatological; antigout;
KW   immunomodulator; antiarrhythmic; cardiant; nootropic; antilipaemic;
KW   nephrotropic; uropathic; neuroprotective; antiparkinsonian; tranquilizer;
KW   antidiabetic; anabolic; hypertensive; vulnerary; gene therapy; cancer;
KW   reproductive system disorder; therapeutic protein.
XX
OS   Unidentified.
XX
PN   US2004010134-A1.
XX
PD   15-JAN-2004.
XX
PF   12-APR-2001; 2001US-00833245.
XX
PR   12-APR-2000; 2000US-0229358P.
PR   25-APR-2000; 2000US-0199384P.
PR   21-DEC-2000; 2000US-0256931P.
XX
PA   (ROSE/) ROSEN C A.
PA   (HASE/) HASELTINE W A.
XX
PI   Rosen CA,  Haseltine WA;
XX
DR   WPI; 2004-090519/09.
XX
PT   New albumin fusion proteins, useful for diagnosing, treating, preventing
PT   or ameliorating diseases or disorders e.g. cancer, anemia, arthritis,
PT   asthma, inflammatory bowel disease or Alzheimer's disease.
XX
```

```
PS   Disclosure; SEQ ID NO 1851; 279pp; English.
XX
CC   The invention relates to a novel albumin fusion protein. The invention
CC   further relates to: a composition comprising the albumin fusion protein
CC   and a pharmaceutical carrier; a kit comprising the composition of the
CC   albumin fusion protein formula; a method of treating a disease or
CC   disorder in a patient comprising the step of administering the albumin
CC   fusion protein; a method of treating a patient with a disease or disorder
CC   that is modulated by Therapeutic protein: X, or its fragment or variant;
CC   a method of extending the shelf life of Therapeutic protein: X, or its
CC   fragment or variant; a nucleic acid molecule comprising a polynucleotide
CC   sequence encoding the albumin fusion protein; a vector comprising the
CC   nucleic acid molecule of the albumin fusion protein; and a host cell
CC   comprising the nucleic acid molecule of the albumin fusion protein. The
CC   albumin fusion protein and its compositions have the following
CC   activities: cytostatic, antianaemic, antiarthritic, antiasthmatic, anti-
CC   HIV, immunosuppressive, antiinflammatory, antipsoriatic, antibacterial,
CC   osteopathic, dermatological, antigout, immunomodulator, antiarrhythmic,
CC   cardiant, nootropic, antilipaemic, nephrotropic, uropathic,
CC   neuroprotective, antiparkinsonian, tranquilizer, antidiabetic, anabolic,
CC   hypertensive, and vulnerary. The albumin fusion protein nucleic acid may
CC   be used in gene therapy to treat disorders. The albumin fusion protein is
CC   useful for diagnosing, treating, preventing or ameliorating diseases or
CC   disorders comprising indication: Y. The diseases or disorders include:
CC   cancer (e.g. leukaemia, colon, bone, breast, liver or lung cancer),
CC   immune or haematopoietic diseases (e.g. anaemia, Hodgkin's disease, acute
CC   lymphocytic anaemia, multiple myeloma, arthritis, asthma, AIDS,
CC   autoimmune disease, inflammatory bowel disease, psoriasis or Lyme
CC   disease), reproductive system disorders (e.g. prostatitis, inguinal
CC   hernia, varicocele, penile carcinoma, ovarian adenocarcinoma or Sertoli-
CC   leydig tumours), musculoskeletal diseases (e.g. giant cell tumours,
CC   Paget's disease, systemic lupus erythematosus, gout, muscular dystrophy
CC   or cachexia), cardiovascular disease (e.g. rhabdomyomas, heart disease,
CC   arrhythmia, cardiac arrest, heat valve disease, hypernatraemia or
CC   hyponatraemia), mixed foetal diseases (e.g. foetal alcohol syndrome,
CC   Down's syndrome, Patau syndrome, Turner's syndrome, Apert syndrome or Tay
CC   -Sachs disease), excretory diseases (e.g. urinary incontinence, urinary
CC   tract infections or renal disorders), neural or sensory disease (e.g.
CC   Alzheimer's disease, Parkinson's disease, cerebral malaria, meningitis,
CC   cerebellar ataxia, attention deficit disorder, autism or obsessive
CC   compulsive disorder), respiratory disease (e.g. emphysema, lung cancer or
CC   occupational lung disease), endocrine diseases (e.g. diabetes, Addison's
CC   disease or glomerulonephritis), digestive diseases (e.g. portal
CC   hypertension, irritable bowel disease, gastric atrophy or pancreatitis)
CC   or connective tissue or epithelial diseases (e.g. Crohn's disease,
CC   scleroderma, wound healing or epidermolysis bullosa). This sequence
CC   represents a therapeutic protein X relating to the albumin fusion protein
CC   of the invention. The sequence listing data for this specification was
CC   dowloaded from the USPTO website.
XX
SQ   Sequence 547 AA;

  Query Match             85.7%;  Score 6;  DB 8;  Length 547;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ASSTDW 6
              ||||||
Db        375 ASSTDW 380


RESULT 8
AEE04690
ID   AEE04690 standard; protein; 547 AA.
XX
AC   AEE04690;
XX
DT   15-JUN-2007  (revised)
DT   26-JAN-2006  (first entry)
XX
DE   Cancer-associated protein SEQ ID NO:8.
XX
KW   cancer; microarray; hybridoma; monoclonal antibody; screening;
KW   RNA interference; diagnosis; cytostatic; neoplasm; BOND_PC; KIAA1754;
KW   KIAA1754 [Homo sapiens]; bA127L20.2; RP11-127L20.4;
KW   hypothetical protein LOC85450;
```

KW hypothetical protein LOC85450 [Homo sapiens]; 2; DANGER; bA127L20;
KW KIAA1754, isoform CRA_a; KIAA1754, isoform CRA_a [Homo sapiens];
KW novel protein; novel protein [Homo sapiens]; unnamed protein product;
KW unnamed protein product [Homo sapiens].
XX
OS Homo sapiens.
XX
PN WO2005107396-A2.
XX
PD 17-NOV-2005.
XX
PF 02-MAY-2005; 2005WO-US014965.
XX
PR 30-APR-2004; 2004US-00836956.
XX
PA (CHIR ) CHIRON CORP.
XX
PI Morris DW, Malandro MS, Lai A, Tse C, Fattaey A;
XX
DR WPI; 2005-769640/78.
DR N-PSDB; AEE04689.
DR PC:NCBI; gi29789287.
XX
PT New cancer-associated (CA) polynucleotide comprising at least 10
PT contiguous nucleotides, useful in preparing a composition for diagnosing
PT or treating cancer.
XX
PS Claim 18; SEQ ID NO 8; 148pp; English.
XX
CC The invention relates to new isolated cancer-associated nucleic acid and
CC polypeptide sequences. Also included are the following: a host cell
CC comprising the recombinant nucleic acid or expression vector; an
CC expression vector comprising the isolated nucleic acid; a microarray for
CC detecting a cancer associated (CA) nucleic acid comprising at least one
CC probe comprising at least 10 contiguous nucleotides of the sequence given
CC in the specification; an isolated polypeptide encoded within an open
CC reading frame of a CA sequence; an isolated antibody or its antigen
CC binding fragment that binds to the polypeptide; a hybridoma that produces
CC the monoclonal antibody; a kit for detecting cancer cells comprising the
CC antibody; a kit for diagnosing the presence of cancer in a test sample,
CC comprising at least one polynucleotide that selectively hybridizes to a
CC CA polynucleotide sequence; a method for detecting a presence or an
CC absence of cancer cells in an individual; an electronic library
CC comprising the polynucleotide or polypeptide or its fragment comprising
CC the CA polynucleotide or polypeptide sequence, or its complement; a
CC method of screening for anticancer activity; a method for detecting
CC cancer associated with expression of a polypeptide in a test cell sample;
CC a method for screening for a bioactive agent capable of modulating the
CC activity of a CA protein (CAP), where the CAP is encoded by the nucleic
CC acid sequence given in the specification; a method for diagnosing cancer;
CC a method for treating cancer; and a method for inhibiting expression of a
CC cancer associated (CA) gene in a cell. Inhibiting expression of a cancer
CC associated (CA) gene in a cell comprises contacting a cell expressing a
CC CA gene with a double stranded RNA comprising a sequence capable of
CC hybridizing to a cancer associated (CA) mRNA corresponding to the
CC polynucleotide sequences given in the specification, in an amount
CC sufficient to elicit RNA interference and inhibiting expression of the CA
CC gene in the cell. The double stranded RNA is provided by introducing a
CC short interfering RNA (siRNA) into the cell by transfection,
CC electroporation or microinjection. The double stranded RNA is provided by
CC introducing a short interfering RNA (siRNA) into the cell by an
CC expression vector. The polynucleotides are useful in preparing a
CC composition for diagnosing or treating cancer. The present sequence
CC represents a cancer-associated protein of the invention. Note: This
CC sequence is not shown in the specification but was obtained in electronic
CC format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences/17.11.2005/.
CC
CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC information from BOND.
XX
SQ Sequence 547 AA;

Query Match 85.7%; Score 6; DB 10; Length 547;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 ASSTDW 6
              ||||||
Db        375 ASSTDW 380


RESULT 9
AEE04692
ID   AEE04692 standard; protein; 547 AA.
XX
AC   AEE04692;
XX
DT   15-JUN-2007  (revised)
DT   26-JAN-2006  (first entry)
XX
DE   Cancer-associated protein SEQ ID NO:10.
XX
KW   cancer; microarray; hybridoma; monoclonal antibody; screening;
KW   RNA interference; diagnosis; cytostatic; neoplasm; BOND_PC; KIAA1754;
KW   KIAA1754 [Homo sapiens]; bA127L20.2; RP11-127L20.4;
KW   hypothetical protein LOC85450;
KW   hypothetical protein LOC85450 [Homo sapiens]; 2; DANGER; bA127L20;
KW   KIAA1754, isoform CRA_a; KIAA1754, isoform CRA_a [Homo sapiens];
KW   novel protein; novel protein [Homo sapiens]; unnamed protein product;
KW   unnamed protein product [Homo sapiens].
XX
OS   Homo sapiens.
XX
PN   WO2005107396-A2.
XX
PD   17-NOV-2005.
XX
PF   02-MAY-2005; 2005WO-US014965.
XX
PR   30-APR-2004; 2004US-00836956.
XX
PA   (CHIR ) CHIRON CORP.
XX
PI   Morris DW,  Malandro MS,  Lai A,  Tse C,  Fattaey A;
XX
DR   WPI; 2005-769640/78.
DR   N-PSDB; AEE04691.
DR   PC:NCBI; gi29789287.
XX
PT   New cancer-associated (CA) polynucleotide comprising at least 10
PT   contiguous nucleotides, useful in preparing a composition for diagnosing
PT   or treating cancer.
XX
PS   Claim 18; SEQ ID NO 10; 148pp; English.
XX
CC   The invention relates to new isolated cancer-associated nucleic acid and
CC   polypeptide sequences. Also included are the following: a host cell
CC   comprising the recombinant nucleic acid or expression vector; an
CC   expression vector comprising the isolated nucleic acid; a microarray for
CC   detecting a cancer associated (CA) nucleic acid comprising at least one
CC   probe comprising at least 10 contiguous nucleotides of the sequence given
CC   in the specification; an isolated polypeptide encoded within an open
CC   reading frame of a CA sequence; an isolated antibody or its antigen
CC   binding fragment that binds to the polypeptide; a hybridoma that produces
CC   the monoclonal antibody; a kit for detecting cancer cells comprising the
CC   antibody; a kit for diagnosing the presence of cancer in a test sample,
CC   comprising at least one polynucleotide that selectively hybridizes to a
CC   CA polynucleotide sequence; a method for detecting a presence or an
CC   absence of cancer cells in an individual; an electronic library
CC   comprising the polynucleotide or polypeptide or its fragment comprising
CC   the CA polynucleotide or polypeptide sequence, or its complement; a
CC   method of screening for anticancer activity; a method for detecting
CC   cancer associated with expression of a polypeptide in a test cell sample;
CC   a method for screening for a bioactive agent capable of modulating the
CC   activity of a CA protein (CAP), where the CAP is encoded by the nucleic
CC   acid sequence given in the specification; a method for diagnosing cancer;
CC   a method for treating cancer; and a method for inhibiting expression of a
CC   cancer associated (CA) gene in a cell. Inhibiting expression of a cancer
CC   associated (CA) gene in a cell comprises contacting a cell expressing a
CC   CA gene with a double stranded RNA comprising a sequence capable of
CC   hybridizing to a cancer associated (CA) mRNA corresponding to the
```

```
CC   polynucleotide sequences given in the specification, in an amount
CC   sufficient to elicit RNA interference and inhibiting expression of the CA
CC   gene in the cell. The double stranded RNA is provided by introducing a
CC   short interfering RNA (siRNA) into the cell by transfection,
CC   electroporation or microinjection. The double stranded RNA is provided by
CC   introducing a short interfering RNA (siRNA) into the cell by an
CC   expression vector. The polynucleotides are useful in preparing a
CC   composition for diagnosing or treating cancer. The present sequence
CC   represents a cancer-associated protein of the invention. Note: This
CC   sequence is not shown in the specification but was obtained in electronic
CC   format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences/17.11.2005/.
CC
CC   Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC   information from BOND.
XX
SQ   Sequence 547 AA;

  Query Match             85.7%;  Score 6;  DB 10;  Length 547;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ASSTDW 6
              ||||||
Db        375 ASSTDW 380


RESULT 10
AEH08642
ID   AEH08642 standard; protein; 547 AA.
XX
AC   AEH08642;
XX
DT   15-JUN-2007  (revised)
DT   15-JUN-2006  (first entry)
XX
DE   Therapeutic protein HSYAB05, SEQ ID 1851.
XX
KW   protein therapy; gene therapy; cancer; cytostatic; BOND_PC; KIAA1754;
KW   KIAA1754 [Homo sapiens]; bA127L20.2; RP11-127L20.4;
KW   hypothetical protein LOC85450;
KW   hypothetical protein LOC85450 [Homo sapiens]; 2; DANGER; bA127L20;
KW   KIAA1754, isoform CRA_a; KIAA1754, isoform CRA_a [Homo sapiens];
KW   novel protein; novel protein [Homo sapiens]; unnamed protein product;
KW   unnamed protein product [Homo sapiens].
XX
OS   Homo sapiens.
XX
PN   US2006084794-A1.
XX
PD   20-APR-2006.
XX
PF   02-NOV-2005; 2005US-00264096.
XX
PR   12-APR-2001; 2001US-00833245.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Haseltine WA;
XX
DR   WPI; 2006-299363/31.
DR   PC:NCBI; gi29789287.
XX
PT   New albumin fusion protein comprises Therapeutic protein X and albumin,
PT   or its fragments or variants, useful for treating, preventing, or
PT   ameliorating, e.g. neural disorders, muscular disorders, renal disorders,
PT   or cancerous diseases.
XX
PS   Disclosure; SEQ ID NO 1851; 257pp; English.
XX
CC   The present invention relates to albumin fusion proteins comprising a
CC   Therapeutic protein X and albumin (AEH06831). The albumin fusion proteins
CC   are useful for treating, preventing, or ameliorating diseases or
CC   disorders that are modulated by Therapeutic protein X by protein or gene
CC   therapy. Diseases include neural disorders, immune system disorders,
CC   muscular disorders, reproductive disorders, gastrointestinal disorders,
```

```
CC   pulmonary disorders, cardiovascular disorders, renal disorders,
CC   proliferative disorders, and/or cancerous diseases. The present sequence
CC   is one such therapeutic protein.
CC
CC   Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC   information from BOND.
XX
SQ   Sequence 547 AA;

  Query Match             85.7%;  Score 6;  DB 11;  Length 547;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ASSTDW 6
              ||||||
Db        375 ASSTDW 380


RESULT 11
AGI51470
ID   AGI51470 standard; protein; 547 AA.
XX
AC   AGI51470;
XX
DT   04-OCT-2007  (first entry)
XX
DE   Human Therapeutic protein X amino acid sequence SEQ ID NO:1851.
XX
KW   albumin; fusion protein; therapeutic; pharmaceutical; vulnerary;
KW   vasotropic; respiratory-gen.; osteopathic; neuroprotective; nephrotropic;
KW   muscular-gen.; immunomodulator; gastrointestinal-gen.; endocrine-gen.;
KW   cytostatic; cardiovascular-gen.; antimicrobial; gene therapy;
KW   wound healing; respiratory disease; reproduction disorder; renal disease;
KW   neurological disease; neoplasm; neoplasia; musculoskeletal disease;
KW   infectious disease; immune disorder; hemopoiesis;
KW   gastrointestinal function disorder; gastrointestinal disease;
KW   endocrine disease; cardiovascular disease; therapeutic protein X;
KW   BOND_PC; KIAA1754; bA127L20.2; RP11-127L20.4;
KW   hypothetical protein LOC85450; 2; DANGER; bA127L20;
KW   KIAA1754, isoform CRA_a; novel protein; unnamed protein product.
XX
OS   Homo sapiens.
XX
PN   US2007099833-A1.
XX
PD   03-MAY-2007.
XX
PF   11-OCT-2006; 2006US-00545766.
XX
PR   12-APR-2001; 2001US-00833245.
PR   02-NOV-2005; 2005US-00264096.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Haseltine WA;
XX
DR   WPI; 2007-494526/48.
DR   PC:NCBI; gi29789287.
XX
PT   New albumin fusion protein, useful for treating, preventing, or
PT   ameliorating diseases, e.g. neoplastic, hematopoietic, reproductive,
PT   cardiovascular, renal, neurological, respiratory, digestive, endocrine,
PT   wound, or infectious diseases.
XX
PS   Disclosure; SEQ ID NO 1851; 259pp; English.
XX
CC   The invention relates to an albumin fusion protein comprising a
CC   Therapeutic protein X and albumin. Also described: (1) a composition
CC   comprising the albumin fusion protein and a pharmaceutical carrier; (2) a
CC   kit comprising the composition; (3) a method of treating a disease or
CC   disorder in a patient; (4) a method of extending the shelf life of
CC   Therapeutic protein X or a fragment of variant of a Therapeutic X; (5) a
CC   method of prolonging the serum half-life of Therapeutic protein X or a
CC   fragment of variant of a Therapeutic X; (6) a nucleic acid molecule
CC   comprising a polynucleotide sequence encoding the albumin fusion protein;
CC   (7) a vector comprising the nucleic acid molecule of (6); and (8) a host
```

```
CC   cell comprising the nucleic acid molecule of (6). The albumin fusion
CC   proteins, nucleic acid molecules, compositions, and methods are useful
CC   for treating, preventing, or ameliorating diseases, disorders or
CC   conditions, e.g. neoplastic, immune, hematopoietic, reproductive,
CC   musculoskeletal, cardiovascular, renal, neurological, respiratory,
CC   digestive, endocrine, wound, or infectious diseases, disorders or
CC   conditions. The present invention provides stabilized, long lasting
CC   formulations of proteinaceous therapeutic molecules that are easily
CC   dispensed, preferably with a simple formulation requiring minimal post-
CC   storage manipulation. The present sequence represents a human theraptic
CC   protein X amino acid sequence, which is used in the exemplification of
CC   the present invention.
CC
CC   Revised record issued on 17-SEP-2007 : Enhanced with precomputed
CC   information from BOND.
XX
SQ   Sequence 547 AA;

  Query Match             85.7%;  Score 6;  DB 12;  Length 547;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ASSTDW 6
              ||||||
Db        375 ASSTDW 380


RESULT 12
ABU60933
ID   ABU60933 standard; protein; 594 AA.
XX
AC   ABU60933;
XX
DT   15-JUN-2007  (revised)
DT   08-MAY-2003  (first entry)
XX
DE   Lung specific protein (LSP) #36.
XX
KW   Human; gene therapy; vaccine; lung specific antigen; cancer diagnosis;
KW   cancer monitoring; cancer staging; cancer imaging; lung cancer;
KW   non-cancerous diseases of the lung; transgenic animal; BOND_PC;
KW   KIAA1754 protein; KIAA1754 protein [Homo sapiens]; GO1747; GO3824;
KW   GO5488; GO7399.
XX
OS   Homo sapiens.
XX
PN   WO200268633-A2.
XX
PD   06-SEP-2002.
XX
PF   21-NOV-2001; 2001WO-US043612.
XX
PR   22-NOV-2000; 2000US-0252500P.
XX
PA   (DIAD-) DIADEXUS INC.
XX
PI   Macina RA,  Recipon H,  Chen S,  Sun Y,  Liu C;
XX
DR   WPI; 2002-713376/77.
DR   PC:NCBI; gi12698053.
XX
PT   New isolated human nucleic acid molecule and polypeptide, useful for
PT   identifying, diagnosing, monitoring, staging, imaging and treating lung
PT   cancer and non-cancerous diseases of the lung.
XX
PS   Claim 11; Page 330-332; 389pp; English.
XX
CC   The invention describes an isolated human nucleic acid (I) encoding any
CC   of 120 10-1533 residue amino acid sequences (S1), given in the
CC   specification, comprising any of 164 179-12421 base pair sequences (S2),
CC   given in the specification. The methods and compositions of the present
CC   invention are useful for identifying, diagnosing, monitoring, staging,
CC   imaging and treating lung cancer and non-cancerous diseases of the lung.
CC   They are also used for identifying lung tissue, monitoring and
CC   identifying and/or designing antagonists of the polypeptide of the
CC   invention, gene therapy, production of transgenic animals and production
```

```
CC   of engineered lung tissue for treatment and research. This is the amino
CC   acid sequence of a lung specific nucleic acid
CC
CC   Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC   information from BOND.
XX
SQ   Sequence 594 AA;

  Query Match             85.7%;  Score 6;  DB 5;  Length 594;
  Best Local Similarity   100.0%;  Pred. No. 2.7e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ASSTDW 6
              ||||||
Db        422 ASSTDW 427


RESULT 13
ABU60982
ID   ABU60982 standard; protein; 594 AA.
XX
AC   ABU60982;
XX
DT   15-JUN-2007  (revised)
DT   08-MAY-2003  (first entry)
XX
DE   Lung specific protein (LSP) #85.
XX
KW   Human; gene therapy; vaccine; lung specific antigen; cancer diagnosis;
KW   cancer monitoring; cancer staging; cancer imaging; lung cancer;
KW   non-cancerous diseases of the lung; transgenic animal; BOND_PC;
KW   KIAA1754 protein; KIAA1754 protein [Homo sapiens]; GO1747; GO3824;
KW   GO5488; GO7399.
XX
OS   Homo sapiens.
XX
PN   WO200268633-A2.
XX
PD   06-SEP-2002.
XX
PF   21-NOV-2001; 2001WO-US043612.
XX
PR   22-NOV-2000; 2000US-0252500P.
XX
PA   (DIAD-) DIADEXUS INC.
XX
PI   Macina RA,  Recipon H,  Chen S,  Sun Y,  Liu C;
XX
DR   WPI; 2002-713376/77.
DR   PC:NCBI; gi12698053.
XX
PT   New isolated human nucleic acid molecule and polypeptide, useful for
PT   identifying, diagnosing, monitoring, staging, imaging and treating lung
PT   cancer and non-cancerous diseases of the lung.
XX
PS   Claim 11; Page 365-367; 389pp; English.
XX
CC   The invention describes an isolated human nucleic acid (I) encoding any
CC   of 120 10-1533 residue amino acid sequences (S1), given in the
CC   specification, comprising any of 164 179-12421 base pair sequences (S2),
CC   given in the specification. The methods and compositions of the present
CC   invention are useful for identifying, diagnosing, monitoring, staging,
CC   imaging and treating lung cancer and non-cancerous diseases of the lung.
CC   They are also used for identifying lung tissue, monitoring and
CC   identifying and/or designing antagonists of the polypeptide of the
CC   invention, gene therapy, production of transgenic animals and production
CC   of engineered lung tissue for treatment and research. This is the amino
CC   acid sequence of a lung specific nucleic acid
CC
CC   Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC   information from BOND.
XX
SQ   Sequence 594 AA;

  Query Match             85.7%;  Score 6;  DB 5;  Length 594;
  Best Local Similarity   100.0%;  Pred. No. 2.7e+02;
```

```
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ASSTDW 6
              ||||||
Db        422 ASSTDW 427


RESULT 14
AAG94691
ID   AAG94691 standard; peptide; 10 AA.
XX
AC   AAG94691;
XX
DT   18-SEP-2001  (first entry)
XX
DE   Human complementary peptide, SEQ ID NO: 885.
XX
KW   Human; complementary peptide; ligand; drug discovery; drug design.
XX
OS   Homo sapiens.
XX
PN   WO200142277-A2.
XX
PD   14-JUN-2001.
XX
PF   13-DEC-2000; 2000WO-GB004776.
XX
PR   13-DEC-1999;   99GB-00029464.
XX
PA   (PROT-) PROTEOM LTD.
XX
PI   Roberts GW,  Heal JR;
XX
DR   WPI; 2001-408419/43.
XX
PT   A set of peptide ligands consisting of specific complementary peptides to
PT   proteins encoded by genes of the human genome, useful in an assay for
PT   screening and identifying of one or more novel peptides which are drug
PT   candidates or pro-drugs.
XX
PS   Example 4; Page 166; 646pp; English.
XX
CC   The invention relates to a set of complementary peptide ligands generated
CC   from the human genome. The complementary peptides interact with their
CC   relevant target proteins encoded in the human genome. They can be used as
CC   reagents in drug discovery and as lead ligands to facilitate drug design
CC   and development. The present sequence is a complementary peptide provided
CC   in the specification
XX
SQ   Sequence 10 AA;

  Query Match             71.4%;  Score 5;  DB 4;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 83;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ASSTD 5
              |||||
Db          5 ASSTD 9


RESULT 15
AEC09392
ID   AEC09392 standard; peptide; 11 AA.
XX
AC   AEC09392;
XX
DT   03-NOV-2005  (first entry)
XX
DE   DNA helicase HEL308 peptide.
XX
KW   antibody identification; multiple sclerosis; neuroprotective;
KW   immune disorder; autoimmune disease; immunosuppressive;
KW   neurological disease; psychiatric disorder; DNA helicase; HEL308.
XX
OS   Synthetic.
XX
```

PN WO2005080985-A2.
XX
PD 01-SEP-2005.
XX
PF 18-FEB-2005; 2005WO-US005146.
XX
PR 18-FEB-2004; 2004US-0545980P.
PR 18-FEB-2004; 2004US-0546062P.
XX
PA (ENTE-) ENTERON LP.
XX
PI Calenoff E;
XX
DR WPI; 2005-630435/64.
XX
PT Detecting disease caused by antibodies that complex with self-molecules
PT in the subject, by identifying antigen molecule on a self molecule of the
PT subject and detecting specific immunoglobulin antibody in biological
PT fluid of subject.
XX
PS Disclosure; Fig 2; 54pp; English.
XX
CC The invention describes a method of detecting a disease in a subject
CC caused or affected by antibodies that complex with self-molecules in the
CC subject comprises identifying antigen molecule on a self molecule of the
CC subject comprising one or more epitopes, and detecting specific
CC immunoglobulin antibody in a biological fluid of the subject, where the
CC antibody forms an immunocomplex with the epitopes on the antigen
CC molecule, where the disease is detected. The method is useful for
CC detecting an autoimmune disease (multiple sclerosis), a neurological
CC disease, or a psychiatric disease in a subject caused or affected by
CC antibodies that complex with self-molecules in the subject. This is the
CC amino acid sequence of a DNA helicase HEL308 peptide that can be used as
CC an epitope fro treatment of multiple sclerosis.
XX
SQ Sequence 11 AA;

Query Match 71.4%; Score 5; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 91;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 ASSTD 5
              |||||
Db          5 ASSTD 9
```

Search completed: July 31, 2008, 17:17:58
Job time : 67.4113 secs

SCORE 3.0